Tata Consultancy Services (TCS) has launched AgentHub: an artificial intelligence-driven platform that will introduce agents to the drug development industry and its highly regulated structure.
AgentHub is part of the TCS ADD (Advanced Drug Development) suite, which will help pharmaceutical and life sciences companies accelerate clinical research, speed up drug development and increase operational efficiency in the sector with a strong regulatory framework in place.
The launch comes at a time when the pharmaceutical industry is increasingly exploring the use of advanced AI technologies to address rising costs, growing data complexity and lengthy drug development timelines. New drugs can take more than a decade to get to market and will cost billions of dollars. Agentic AI can reduce inefficiencies, make mistakes less likely, and have a role in supporting researchers throughout the development process, industry experts say, or to reduce cost.
TCS believes AgentHub is designed to operate as a new platform that is not only a digital assistant but rather as an AI workforce in the form of role-based agents that can take on specific roles in clinical development and pharmacovigilance. TCS says AgentHub is a new operating model that doesn't just treat AI as a digital assistant but as an AI workforce where professionals can also be responsible for clinical development and pharmacovigilance.
One of the major challenges in AI adoption in pharmaceutical sectors is trust and regulatory acceptance. Many companies have tried AI-powered tools and copilots and have also tried them out with AI-enabled products in their labs. But in reality, there is no easy way to scale such products and solutions into production-ready systems because these solutions are not always accountable, and compliance is a major challenge for companies; they can never be trusted, and oversight and accountability are a big concern.
TCS believes AgentHub addresses this by making sure AI-driven action is traceable, reviewable and compliant with industry regulations. The company says AI agents are not the sole decision-makers and human experts are the ones who make final decisions; humans will still be there to guide decisions, and AI agents are the team members that are helping to improve productivity and efficiency.
AgentHub provides a wide range of specialised AI agents for various drug development phases. They include study design optimisation assistants, protocol digitisation agents, clinical data review workers, medical monitoring assistants and regulatory documentation support systems. By automating a lot of tedious administrative and analytical work, scientists, researchers and healthcare professionals can focus on more valuable work like innovation, strategic decision-making and patient outcomes.
Agentic AI is a phenomenon that is rapidly growing and is a process of transformation of the industry throughout the healthcare and pharmaceutical sector. While traditional AI systems only provide insights or recommendations, agentic AI systems can individually plan, coordinate and execute multi-step workflows.
This capability helps organisations to better manage massive amounts of clinical data, get regulatory approval faster and also improve clinical trial completion times. Experts say these improvements in AI technology could cut development time and improve the quality and consistency of research outcomes.
TCS has highlighted flexibility as one of AgentHub's major advantages. Organisations can use the platform in a variety of ways: AI copilots, AI workers-as-a-service or custom-built agents operating within a regulated framework. This allows pharmaceutical companies to adopt agentic AI gradually based on their operational maturity and regulatory comfort levels.
Now that competition in the pharmaceutical industry is ratcheting up, and treatments have to get there faster than ever, technology like AgentHub could become even more important in the future of healthcare. TCS is applying automation, governance, and human influence as a bridge between the emerging AI applications and clinical activities in a clinical context. If adopted globally, AgentHub would revolutionise the way pharmaceutical companies conduct research, conduct clinical trials and deliver life-saving drugs to patients around the world.
